This activity is provided by Med Learning Group.
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Resources
The Alzheimer’s Association offers a plethora of clinical resources on the disease, including:
Other References
NCT02442765. Efficacy, safety and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type. 2/13/23 (https://clinicaltrials.gov/ct2/show/NCT02442765). Accessed 10/31/23.
NCT01584440. Efficacy, safety and tolerability study of AVP-923 (dextromethorphan/quinidine) for treatment of symptoms of agitation in participants with Alzheimer’s disease. 11/26/21 (https://clinicaltrials.gov/ct2/show/NCT01584440). Accessed 10/31/23.
NCT02442778. Efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in participants with dementia of the Alzheimer’s type. 9/9/22 (https://clinicaltrials.gov/ct2/show/NCT02442778). Accessed 10/31/23.
NCT05543681. IGC-AD1 trial on agitation in dementia due to Alzheimer’s (IGC-AD1-P2). 10/17/23 (https://clinicaltrials.gov/ct2/show/NCT05543681). Accessed 10/31/23.
NCT05239390. SCI-110 for Alzheimer disease and agitation. 2/14/22 (https://clinicaltrials.gov/ct2/show/NCT05239390). Accessed 10/31/23.
Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer’s disease and dementia with Lewy bodies. J Neurosci. 2006;26:467-478.
Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA. 2003;289:210-216.
Weiner MF. Impact of delirium on the course of Alzheimer disease. Arch Neurol. 2012;69:1639-1640.
